IRTC IRhythm Technologies Inc.

iRhythm Technologies Releases 2024 Corporate Sustainability Report That Demonstrates Ongoing Commitment to Culture of Quality and Sustainability

iRhythm Technologies Releases 2024 Corporate Sustainability Report That Demonstrates Ongoing Commitment to Culture of Quality and Sustainability

Report highlights progress against key sustainability initiatives that reflect iRhythm’s commitment to delivering better data, better insights, and better health for all

SAN FRANCISCO, April 16, 2025 (GLOBE NEWSWIRE) -- . (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today announced that it has published its , highlighting the company’s efforts to build a sustainable and inclusive future.

“iRhythm’s core mission is to create a better world for patients by delivering better health and better insights through our trusted solutions and innovative technologies,” said Sumi Shrishrimal, iRhythm’s Chief Risk Officer and leader of Sustainability and Impact. “We accomplish this by being a responsible, ethical, and inclusive company dedicated to the highest standards of quality and excellence across our business as we execute upon our long-term strategic growth plan. I am so proud of the work our teams do every day, and our 2024 Corporate Sustainability Report reflects how we make cardiac monitoring more accessible, how we enable providers to better detect and prevent disease, and how we impact our communities as a global company.”

The 2024 Corporate Sustainability Report details sustainability accomplishments across four key pillars:

  • Quality and Sustainable Technology Innovation highlights include enhancing our quality systems, improving our customers’ experience through Electronic Health Record (EHR) integration and innovative product launches, securing a strategic licensing agreement to advance connected patient care, and forming an Artificial Intelligence (“AI”) Governance Steering Committee to address AI risks and opportunities in alignment with the company’s strategic goals
  • Access and Health Equity highlights include expanding globally by launching commercially in four European countries (Austria, the Netherlands, Spain, and Switzerland) and receiving regulatory approval from the Japanese Pharmaceutical and Medical Device Agency for the Zio® 14-day, long-term continuous ECG monitoring system
  • Workforce and Inclusion highlights include refreshing our core values to define the workplace culture we would like to shape going forward, revising our code of conduct to provide employees with resources and guidance needed to operate with unquestionable integrity, and introducing new recognition opportunities to celebrate employees who elevate the company’s values through their work
  • Environmental Impact highlights include completing inventory of Scope 3 greenhouse gas emissions, achieving 89.5% landfill waste diversion across our operations, obtaining ISO 14001:2015 Environmental Management Systems Certification, completing a life cycle analysis (LCA) of our products, and being named to Newsweek’s list of America’s Greenest Companies for 2025

For more information about iRhythm’s corporate sustainability efforts, please visit our Corporate Sustainability page .

About iRhythm Technologies

iRhythm is a leading digital health care company that creates trusted solutions that detect, predict, and prevent disease. Combining wearable biosensors and cloud-based data analytics with powerful proprietary algorithms, iRhythm distills data from millions of heartbeats into clinically actionable information. Through a relentless focus on patient care, iRhythm’s vision is to deliver better data, better insights, and better health for all. To learn more, please visit .

Investor Contact

Stephanie Zhadkevich

Media Contact

Kassandra Perry



EN
16/04/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on IRhythm Technologies Inc.

Irhythm Technologies Inc: 2 directors

Two Directors at Irhythm Technologies Inc sold 10,510 shares at between 120.552USD and 125.000USD. The significance rating of the trade was 72/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's director...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

 PRESS RELEASE

iRhythm Launches Zio® Long-Term Continuous Monitoring Service in Japan...

iRhythm Launches Zio® Long-Term Continuous Monitoring Service in Japan as the Zio® ECG Recording and Analysis System, Advancing AI-Powered Arrhythmia Detection iRhythm Zio® Long-Term Continuous Monitoring (LTCM) system — commercially introduced in Japan as the Zio® ECG Recording and Analysis System — brings AI-powered, continuous, uninterrupted ECG monitoring for up to 14 days to JapanLaunch is timely amid a growing demand for early, accurate detection of arrhythmias in Japan, the second largest ambulatory cardiac monitoring market in the world, where the prevalence is expected to rise alon...

 PRESS RELEASE

iRhythm Technologies Announces First Quarter 2025 Financial Results

iRhythm Technologies Announces First Quarter 2025 Financial Results SAN FRANCISCO, May 01, 2025 (GLOBE NEWSWIRE) --  (NASDAQ: IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the three months ended March 31, 2025. First Quarter 2025 Financial Highlights Revenue of $158.7 million, a 20.3% increase compared to first quarter 2024Gross margin of 68.8%, a 250-basis point increase compared to first quarter 2024Unrestricted cash, cash equivalents, and marketable securities of $520....

 PRESS RELEASE

iRhythm Technologies to Present at the Bank of America Securities 2025...

iRhythm Technologies to Present at the Bank of America Securities 2025 Health Care Conference SAN FRANCISCO, April 29, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today announced the company will be participating in the upcoming Bank of America Securities 2025 Health Care Conference. iRhythm’s management is scheduled to present on Tuesday, May 13, 2025, 3:40 p.m. Pacific Time/6:40 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presenta...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch